AstraZeneca to pay $68.5 million in Seroquel marketing case

Share this content:
Pharmaceutical giant AstraZeneca has agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced. The medication is approved to treat schizophrenia and bipolar disorder. But it was also being prescribed for elderly patients with dementia, according to published reports.

Next Article in Products